guselkumab

targets

all catalysts(14)

News(10)

• Lilly, Foghorn part ways; Wave’s FDA-approved plans
  The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
  biopharma_dive · 3d ago
• 6 immunology targets to sustain a mammoth I&I market
  Johnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…
  biospace · 7d ago
• Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
  Spyre's three-pronged approach to inflammatory bowel disease continues to pay off, with the biotech's anti-IL-23 antibody notching a phase 2 win.
  fiercebiotech · 27d ago
• MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
  MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
  fiercebiotech · 1mo ago
• J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
  J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
  biopharma_dive · 2mo ago
• Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
  Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
  biopharma_dive · 2mo ago
• Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
  The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
  biopharma_dive · 3mo ago
• AstraZeneca seeks path for failed antibody; Imfinzi, Tremfya get label expansions
  🔎 AstraZeneca narrows path for failed antibody: The company announced last summer that its monoclonal antibody anselamimab missed the primary endpoint in a pair of Phase 3 trials for patients with…
  endpoints · 4mo ago
• Avalo shares spike on skin drug data; BioNTech to cut staff
  Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.
  biopharma_dive · 5mo ago
• J&J's IBD combo fails Phase 2 studies, but will move into pivotal testing
  Johnson & Johnson will move a treatment for inflammatory bowel disease into Phase 3 studies despite the therapy's failure in two mid-stage trials. The company said that JNJ-4804, a combination of t…
  endpoints · 5mo ago